Literature DB >> 11677115

A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line.

R Supino1, P Perego, L Gatti, C Caserini, C Leonetti, M Colantuono, V Zuco, N Carenini, G Zupi, F Zunino.   

Abstract

Based on the role of p53 in the control of apoptosis following DNA damage, the status of the TP53 gene has been implicated as a major determinant of tumour responsiveness to cytotoxic therapies. In spite of the high frequency of TP53 mutations, small-cell lung cancer (SCLC) is recognised as one of the most chemoresponsive solid tumours. Since the relevance of the TP53 gene status in the modulation of tumour responsiveness is dependent on the molecular/biological context, in the present study, we have examined the relationship between chemosensitivity and susceptibility to apoptosis of a TP53-mutant human SCLC cell line. The cell line, in spite of TP53 mutation, retained an efficient response to genotoxic stress as documented by cells ability to modulate the p53 protein, arrest in the G1 and G2 phases of the cell cycle and its marked susceptibility to apoptosis following treatment with DNA damaging agents. Exposure to DNA-damaging agents caused an increase of c-Myc, a DNA damage-responsive transcription factor. An analysis of damage-induced apoptosis in the presence of an anti-Fas/CD95 inhibitory antibody indicated that Fas/CD95 was not required for the apoptotic response. The results support an implication of c-myc in sensitising cells to apoptosis, since inhibition of c-Myc expression with an antisense oligodeoxynucleotide (AS-ODN) almost abolished the drug-induced apoptotic response. In conclusion, the present results support a role for c-myc in the induction of apoptosis by genotoxic stress in the absence of a functional p53 and provide new insights into the mechanisms that may influence apoptosis in TP53-mutant cells. Elucidation of this pathway and of the possible cooperation with p53-dependent mechanisms may provide a basis for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11677115     DOI: 10.1016/s0959-8049(01)00268-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

Review 1.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

2.  Silver nanoparticles from Dendropanax morbifera Léveille inhibit cell migration, induce apoptosis, and increase generation of reactive oxygen species in A549 lung cancer cells.

Authors:  Verónica Castro Aceituno; Sungeun Ahn; Shakina Yesmin Simu; Chao Wang; Ramya Mathiyalagan; Deok Chun Yang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-06-01       Impact factor: 2.416

3.  Cyclooxygenase (COX)-2 and granulosa cell apoptosis in vitro.

Authors:  Angela S Caffrey; William C Patton; Johannah U Corselli; Ron E Swensen; Alan King; Philip J Chan
Journal:  J Assist Reprod Genet       Date:  2002-12       Impact factor: 3.412

4.  Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis and autophagy in oral cancer SSC-4 cells.

Authors:  Alexandra Iulia Irimie; Cornelia Braicu; Oana Zanoaga; Valentina Pileczki; Claudia Gherman; Ioana Berindan-Neagoe; Radu Septimiu Campian
Journal:  Onco Targets Ther       Date:  2015-02-20       Impact factor: 4.147

5.  Cell survival following radiation exposure requires miR-525-3p mediated suppression of ARRB1 and TXN1.

Authors:  Anne Kraemer; Zarko Barjaktarovic; Hakan Sarioglu; Klaudia Winkler; Friederike Eckardt-Schupp; Soile Tapio; Michael J Atkinson; Simone Moertl
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

6.  IDN 5390: an oral taxane candidate for protracted treatment schedules.

Authors:  G Pratesi; D Laccabue; C Lanzi; G Cassinelli; R Supino; M Zucchetti; R Frapolli; M D'Incalci; E Bombardelli; P Morazzoni; A Riva; F Zunino
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.